Castle Biosciences has launched a 487-gene test, with some reports indicating it is intended for guiding treatment selection for atopic dermatitis. The test, known as AdvanceAD-Tx, has received approval from the New York State Department of Health. The launch of the test has also been recognized with a MedTech Breakthrough Award for genomics innovation.